Imfinzi Cost in the USA 2025: Price, Treatment for Lung Cancer, and Insurance Coverage
Imfinzi Cost in the USA 2025: What Patients Need to Know Imfinzi (durvalumab) has become a vital immunotherapy option for patients with lung cancer in the United States, but its price remains a major concern in 2025. The average cost of a single Imfinzi infusion is estimated at $10,000–$12,000, which means that annual treatment expenses can easily exceed $140,000 per year before insurance or assistance programs are applied. For patients and caregivers, understanding the true cost of Imfinzi involves more than just the drug’s wholesale price. Factors such as insurance coverage, Medicare Part B rules, infusion center administration fees, and manufacturer co-pay assistance all play a role in determining what you will actually pay out-of-pocket. The good news is that programs like AstraZeneca Access 360 and patient savings support can dramatically lower costs, sometimes reducing co-pays to as little as $0 for eligible patients. In this updated 2025 guide, we provide detailed price breakdowns, comparisons with other immunotherapies like Keytruda and Opdivo, insurance coverage insights, and 20 frequently asked questions (FAQs) to help you navigate Imfinzi’s financial impact.
Read More
